Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone.

摘要

Hypertension continues to be the single most important cause of morbidity and mortality worldwide. The most recent United States National Health and Nutrition Examination Survey (NHANES) data suggests that blood pressure (BP) control continues to improve in all demographic groups, with 50% of all persons with hypertension and more than 65% of persons also being treated for hypertension currently controlled to the minimum goal of < 140/90 mm Hg. Despite these successes, the pathogenesis of hypertension remains extremely heterogeneous and, since most patients require >=2 antihypertensive agents to control BP, the hypertension community continues to look for new and innovative pathophys-iologic approaches for BP control.